10-Q: Celldex Reports Q3 2025 Results, Advances Barzolvolimab

Celldex Therapeutics reported increased net losses in Q3 2025 due to higher R&D expenses for barzolvolimab, while maintaining sufficient liquidity through 2027 and advancing multiple clinical programs.

Summary

• Net loss increased to $67.0 million for the three months ended September 30, 2025, compared to $42.1 million for the same period in 2024.
• Net loss for the nine months ended September 30, 2025, was $177.4 million, compared to $110.8 million for the same period in 2024.
• Total revenues decreased to $0 for the three months ended September 30, 2025, from $3.2 million in the prior year period, and to $1.4 million for the nine months from $5.8 million in 2024.
• Research and development (R&D) expenses rose to $62.9 million in Q3 2025 (from $45.3 million in Q3 2024) and to $169.7 million for the nine months (from $116.6 million in 2024), primarily driven by barzolvolimab clinical trials and manufacturing.
• Cash, cash equivalents, and marketable securities totaled $583.2 million as of September 30, 2025.
• The company believes current liquidity is sufficient to fund planned operations through 2027.
• Initiated two Phase 3 studies (EMBARQ-CSU1 and EMBARQ-CSU2) for barzolvolimab in Chronic Spontaneous Urticaria (CSU) in July 2024, with enrollment expected to be completed in summer 2026.
• Discontinued development of barzolvolimab in Eosinophilic Esophagitis (EoE) in August 2025 due to lack of clinical improvement despite mast cell depletion.
• Plans to initiate a global Phase 3 study for barzolvolimab in Cold Urticaria (ColdU) and Symptomatic Dermographism (SD) in December 2025.
• Presented positive single ascending dose data for CDX-622 (bispecific antibody) in healthy volunteers in October 2025, showing good pharmacokinetic profile and dose-dependent reductions in serum tryptase.
• Appointed Teri Lawver as Chief Commercial Officer, effective November 10, 2025.

Sentiment

Score: 5

Explanation: The company shows strong clinical progress with barzolvolimab advancing to Phase 3 in CSU and planned Phase 3 in CIndU, and positive early data for CDX-622. However, this progress comes with significantly increased net losses and R&D expenses, and a substantial decrease in revenue. While liquidity is currently sufficient, the high burn rate and need for future capital raises introduce financial uncertainty. The discontinuation of the EoE program is a setback, though expected in drug development.

Positives

• Strong liquidity position with $583.2 million in cash, cash equivalents, and marketable securities, projected to fund operations through 2027.
• Barzolvolimab Phase 3 studies in CSU are ongoing, with enrollment expected to complete in summer 2026.
• Positive long-term follow-up data for barzolvolimab in CSU (76 weeks) showed sustained complete response (41% for 150 mg Q4W, 35% for 300 mg Q8W) and improved quality of life.
• Barzolvolimab Phase 2 study in CIndU (ColdU and SD) achieved primary efficacy endpoint and all secondary endpoints, demonstrating sustained efficacy and favorable safety over 20 weeks.
• Positive Phase 1b data for barzolvolimab in Prurigo Nodularis (PN) showed rapid and durable reductions in itch and healing of skin lesions.
• Initiated Phase 2 studies for barzolvolimab in PN (April 2024) and Atopic Dermatitis (AD) (December 2024), expanding the drug's potential indications.
• CDX-622 Phase 1a study in healthy volunteers showed positive single ascending dose data, with good pharmacokinetic profile and dose-dependent reductions in serum tryptase, indicating mast cell inhibition and depletion.
• Successful scale-up of barzolvolimab drug substance manufacturing and completion of drug product manufacturing into pre-filled syringes for Phase 3 trials.
• Spermatogenesis fully recovered in non-human primates in chronic toxicology study for barzolvolimab, supporting continued development.
• Appointment of a Chief Commercial Officer indicates preparation for potential commercialization.

Negatives

• Net loss significantly increased to $67.0 million for the three months ended September 30, 2025, from $42.1 million in the prior year period, a 59% increase.
• Net loss for the nine months ended September 30, 2025, increased to $177.4 million from $110.8 million in the prior year period, a 60% increase.
• Total revenues decreased to $0 for the three months ended September 30, 2025, from $3.2 million in the prior year period, a 100% decrease.
• Total revenues decreased to $1.4 million for the nine months ended September 30, 2025, from $5.8 million in the prior year period, a 76% decrease.
• Investment and other income, net, decreased by $3.4 million (34%) for the three months and $5.5 million (19%) for the nine months due to lower cash and investment balances.
• Discontinuation of barzolvolimab development in Eosinophilic Esophagitis (EoE) due to lack of clinical improvement in symptoms or endoscopic assessment, despite meeting the primary endpoint of mast cell depletion.
• Recurring losses and significant cash burn ($147.0 million used in operating activities for the nine months ended September 30, 2025).

Risks

• Dependence on product candidates still in development stages.
• Ability to successfully complete research and further development, including preclinical and clinical studies.
• Anticipated timing for preclinical development, regulatory submissions, commencement and completion of clinical trials, and product approvals.
• Ability to negotiate strategic partnerships for drug candidates.
• Ability to manage multiple clinical trials for a variety of drug candidates at different stages.
• Cost, timing, scope, and results of ongoing preclinical and clinical testing.
• Expectations of product and development candidate attributes (pharmaceutical properties, efficacy, safety, dosing).
• Cost, timing, and uncertainty of obtaining regulatory approvals.
• Availability, cost, delivery, and quality of clinical management services from CRO partners.
• Availability, cost, delivery, and quality of clinical and commercial-grade materials from manufacturing facility or contract manufacturers.
• Ability to commercialize drug candidates and market growth.
• Ability to develop and commercialize products before competitors that are superior to alternatives.
• Ability to develop technological capabilities, identify novel targets, exploit existing platforms, and expand focus.
• Cost of paying the regulatory approval milestone under the Kolltan merger and settlement agreement.
• Ability to raise sufficient capital to fund preclinical and clinical studies and meet long-term liquidity needs on acceptable terms. Inability to raise funds could lead to delays, discontinuation of programs, early licensing, or sale of the business.
• Additional equity financings may be dilutive to stockholders.
• Debt financings may involve significant cash payment obligations and restrictive covenants.
• Licensing or strategic collaborations may reduce economic potential from products.
• Ability to protect intellectual property rights and avoid intellectual property litigation.
• Ability to develop and commercialize products without infringing third-party intellectual property rights.
• Historically, results from preclinical testing and early clinical trials (through Phase 2) have often not been predictive of results obtained in later clinical trials.
• Future delays or failures to obtain regulatory approvals, failures of clinical trials, or other failures to achieve a commercially viable product may lead to impairment losses on IPR&D assets.

Future Outlook

The company expects revenue to remain relatively consistent over the next twelve months, with quarterly fluctuations. Personnel, facility, and general and administrative expenses are anticipated to increase due to expanded barzolvolimab development and commercial planning. Product development expenses are also expected to rise due to manufacturing Process Performance Qualification (PPQ) activities. Investment and other income is projected to decrease due to lower cash and investment balances. The company believes its current cash, cash equivalents, and marketable securities of $583.2 million are sufficient to fund planned operations through 2027, though this could be impacted by a potential cash payment for a future milestone under the Settlement Agreement with SRS. The company may seek additional capital through licensing, business combinations, debt, or equity offerings to meet long-term liquidity needs beyond 2027.

Management Comments

• We believe that the cash, cash equivalents and marketable securities at the filing date of this Quarterly Report on Form 10-Q will be sufficient to meet estimated working capital requirements and fund planned operations for at least the next twelve months from the date of issuance of these financial statements.
• We believe these results strongly support the further development of barzolvolimab in CSU.
• We believe these results strongly support the further development of barzolvolimab in CIndU and Celldex plans to initiate a global Phase 3 study in ColdU and SD in December 2025.
• We are encouraged with these findings and believe these data strongly support continued development of barzolvolimab.
• Combined neutralization of SCF and TSLP with CDX-622 is expected to simultaneously reduce tissue mast cells and inhibit Type 2 inflammatory responses to potentially offer enhanced therapeutic benefit in inflammatory and fibrotic disorders.
• We believe our most critical accounting policies include accounting for contingent consideration, revenue recognition, intangible and long-lived assets, research and development expenses and stock-based compensation expense.
• We expect revenue to remain relatively consistent over the next twelve months, although there may be fluctuations on a quarterly basis.
• We expect personnel expenses to increase over the next twelve months as a result of additional headcount to support the expanded development of barzolvolimab.
• We expect product development expenses to increase over the next twelve months as a result of the expanded development of barzolvolimab, including manufacturing PPQ activities planned for the fourth quarter of 2025 and throughout 2026, although there may be fluctuations on a quarterly basis.
• We expect general and administrative expenses to increase over the next twelve months as a result of the expanded development of barzolvolimab and an increase in commercial planning efforts, although there may be fluctuations on a quarterly basis.
• We expect investment and other income to decrease over the next twelve months due to lower levels of cash and investment balances, although there may be fluctuations on a quarterly basis.
• We believe that the cash, cash equivalents and marketable securities at September 30, 2025 are sufficient to meet estimated working capital requirements and fund current planned operations through 2027.
• We expect that cash used in operating activities will increase over the next twelve months as a result of the expanded development of barzolvolimab.

Industry Context

Celldex Therapeutics operates in the biopharmaceutical sector, specifically focusing on mast cell biology and developing therapeutic antibodies for severe inflammatory, allergic, autoimmune, and other diseases. The company's lead candidate, barzolvolimab, targets the KIT receptor, a mechanism relevant to a broad range of mast cell-mediated conditions. The development of bispecific antibodies like CDX-622 represents a trend towards multi-target approaches in inflammatory diseases, aiming for enhanced therapeutic benefits by addressing complementary pathways. The discontinuation of the EoE program highlights the challenges in identifying key drivers for complex inflammatory diseases, even when a drug successfully targets a presumed mechanism (mast cell depletion). The initiation of Phase 3 trials for CSU and planned Phase 3 for CIndU positions Celldex to potentially compete in significant dermatology and allergy markets, where existing treatments may be inadequate for a substantial portion of patients.

Management Changes

Corporate Governance

Legal Proceedings

• The company previously settled litigation with Shareholder Representative Services LLC (SRS) regarding contingent milestone payments related to the Kolltan acquisition. All milestone payments were replaced with new terms, including a future $52.5 million payment upon the first regulatory approval of a Surviving Company Product.

Stakeholder Impact

• Shareholders: Potential for dilution from future equity financings; increased R&D spend and net losses impact profitability; clinical progress in key programs (CSU, CIndU, PN, AD) could drive future value; discontinuation of EoE program reduces potential market but focuses resources.
• Employees: Increased headcount expected to support barzolvolimab development; new Chief Commercial Officer appointment indicates growth in commercial planning; stock-based compensation is a significant component of R&D and G&A expenses.
• Customers/Patients: Continued development of barzolvolimab aims to provide new therapeutic options for severe inflammatory and allergic diseases where current treatments are inadequate; discontinuation of EoE program means no new treatment from Celldex for that condition.
• Creditors: Strong cash position provides security in the short to medium term; potential future debt financings could introduce new obligations and covenants.
• Suppliers/Partners: Ongoing contract manufacturing and research agreements (e.g., with Rockefeller University, CDMOs) are critical for drug development and supply chain.

Next Steps

• Complete enrollment for EMBARQ-CSU1 and EMBARQ-CSU2 Phase 3 studies in CSU by summer 2026.
• Present data from the open label extension (OLE) of the Phase 2 CIndU study in the first quarter of 2026.
• Initiate a global Phase 3 study for barzolvolimab in ColdU and SD in December 2025.
• Present initial data from the Phase 2 subcutaneous study in Prurigo Nodularis (PN) in the second half of 2026.
• Present initial data from the Phase 2 study in Atopic Dermatitis (AD) in the second half of 2026.
• Plan for barzolvolimab drug product Process Performance Qualification (PPQ) activities in 2026.
• Continue enrollment for the multiple ascending doses portion (Part 2) of the CDX-622 Phase 1 study.
• Add a subcutaneous formulation of CDX-622 to the Phase 1 study in 2025.
• Relocate existing New Haven operations to a new leased facility in 2026.
• Potentially raise additional capital through various means to meet long-term liquidity needs.

Key Dates

Recommendation

Celldex Therapeutics is in a critical development phase, with its lead asset, barzolvolimab, advancing into Phase 3 for CSU and planned Phase 3 for CIndU, alongside promising early-stage data for CDX-622. These clinical advancements are significant and could unlock substantial value if successful. However, the company is experiencing a substantial increase in net losses and R&D expenses, reflecting a high burn rate typical for a clinical-stage biopharmaceutical company. While current liquidity is projected to last through 2027, the need for future capital raises and the inherent risks of clinical development (as evidenced by the EoE program discontinuation) introduce considerable uncertainty. The appointment of a Chief Commercial Officer signals future commercialization intent, but profitability remains distant. Given the mixed financial performance against strong clinical progress, a 'hold' recommendation is appropriate for investors to monitor the ongoing Phase 3 trial results and the company's ability to manage its cash burn and secure future financing without excessive dilution.

Keywords

Barzolvolimab, CDX-0159, Chronic Spontaneous Urticaria, CSU, Chronic Inducible Urticaria, CIndU, Cold Urticaria, Symptomatic Dermographism, Prurigo Nodularis, Atopic Dermatitis, Mast Cell Biology, Biopharmaceutical, Clinical Trials, Phase 3, CDX-622, Bispecific Antibody, Inflammatory Diseases, SEC Filing, 10-Q, Drug Development, Clinical Development, Therapeutics, Immunology